Further, using a transient CRISPR-mediated gene knocking out strategy on the mouse β2-microglobulin, we showed that TSPY could be processed/degraded through proteosomes, likely resulting in TSPY-specific peptides capable of forming MHC-I complexes on the cell surface of tumor cells, activating the CD8+ cytotoxic T cells and killing of the positive tumor cells [61]. Here, TSPY1 is linked to neoplasm.